Novo Nordisk dodges antitrust law in swoop for Metsera, Pfizer says
Pfizer has heavily criticized Novo Nordisk’s bid for Metsera, calling it an attempt by a dominant company to illegally suppress competition by acquiring an “emerging challenger.” Denmark’s Novo Nordisk has structured...To view the full article, register now.
Already a subscriber? Click here to view full article